Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

Trikafta. Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del

tezacaftor
pulmonary function test
cystic fibrosis transmembrane conductance regulator
dornase alfa
forced expiratory volume
  • 55 views
  • 26 Jan, 2021
  • 74 locations
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations

processing (tezacaftor) in patients with W1282X CFTR. In the current study, the investigators propose to directly test the efficacy of tezacaftor/ivacaftor (TEZ/IVA) and Trikafta for W1282X CFTR therapy in

tezacaftor
ivacaftor
cftr gene
nonsense mutation
cystic fibrosis transmembrane conductance regulator
  • 5 views
  • 10 May, 2021
  • 1 location
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination therapy in CF subjects

  • 0 views
  • 23 Sep, 2021
  • 17 locations
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor, tezacaftor and ivacaftor triple combination therapy (Kaftrio

tezacaftor
elexacaftor
ivacaftor
fibrosis
spirometry
  • 52 views
  • 12 Jul, 2021
  • 8 locations
The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis

This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.

  • 0 views
  • 11 Mar, 2021
  • 1 location
Personalized Theratyping Trial

The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

cftr modulators
  • 0 views
  • 26 Jan, 2021
  • 1 location
Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function

To obtain prospective real world data of the effect of lumacaftor/ivacaftor or tezacaftor/ ivacaftor on small airway disease in children aged 6-18 years with cystic fibrosis (CF) homozygous for

  • 1 views
  • 26 Jan, 2021
  • 2 locations
Home-Reported Outcomes in People With Cystic Fibrosis Taking Highly Effective CFTR Modulator Therapy

This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR). Individuals taking elexacaftor/tezacaftor/ivacaftor (ETI) may be

elexacaftor
fibrosis
tezacaftor
ivacaftor
  • 0 views
  • 22 Sep, 2021
  • 1 location
Impact of Triple Combination CFTR Therapy on Sinus Disease.

The study's main goal is to observe how effective elexacaftor-tezacaftor-ivacaftor is for improving the symptoms and signs of CF-related sinus disease.

  • 0 views
  • 19 Mar, 2021
  • 1 location
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

This study will evaluate the performance of wearable technology in cystic fibrosis (CF) participants taking commercial Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) utilizing a fully

tezacaftor
elexacaftor
ivacaftor
fibrosis
forced expiratory volume
  • 0 views
  • 09 Sep, 2021
  • 17 locations